Filing Flows › Protalix BioTherapeutics (PLX) › Q1 2026
Protalix BioTherapeutics (PLX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Protalix BioTherapeutics (PLX) reported revenue of $33.8M for the first quarter 2026 (Q1 2026), +234% from a year earlier and +270% from the quarter before. Operating margin was 62.7%, net earnings $18.3M (54.3% of revenue).
Protalix BioTherapeutics, Q1 2026: revenue $33.8M (+234% year over year), operating margin 62.7%, net earnings $18.3M, operating cash flow $22.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $33.8M | +270% | +234% |
| Operating profit | $21.1M | — | — |
| Net earnings | $18.3M | — | — |
| Operating cash flow | $22.0M | +985% | — |
| Free cash flow | $21.3M | 13× | — |
What changed
Revenue was $33.8M in Q1 2026, up 234% year over year and up 270% from the previous quarter. LICENSE AND R&D SERVICES was the largest line at 78% of revenue. LICENSE AND R&D SERVICES added $26.2M year over year (up 22214%), 111% of the total change. GOODS declined 26%.
Operating profit was $21.1M, a 62.7% margin (up 103.6 points year over year). Total costs fell 12% while revenue rose 234%. The fastest-growing cost line was Research & development (+56%). Net earnings were $18.3M. The effective tax rate was 13.4%.
Operating cash flow was $22.0M, 120% of net earnings. Non-cash charges added back $404K of depreciation and $532K of share-based compensation. Working capital and other items added $2.8M. Capital expenditures of $761K left free cash flow of $21.3M.
Questions
What was Protalix BioTherapeutics' revenue in the first quarter 2026?
Protalix BioTherapeutics (PLX) reported revenue of $33.8M for the first quarter 2026 (Q1 2026), +234% from a year earlier and +270% from the quarter before.
Was Protalix BioTherapeutics profitable in the first quarter 2026?
Operating profit was $21.1M (62.7% of revenue) and net earnings $18.3M.